How to Use PT-141 (Bremelanotide): Dosing and Protocol Guide
Complete guide to PT-141 dosing (0.5–2mg), timing (1–4 hours before), administration routes, and managing side effects like nausea and flushing.
Overview
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that increases sexual desire and arousal in both men and women. It works centrally (in the brain) rather than peripherally, making it effective for both psychological and physiological sexual dysfunction. This guide covers dosing, timing, and side effect management.
What You Need
- PT-141 vial (10mg) or nasal spray
- Bacteriostatic water (2mL, for injectable)
- Insulin syringes (U-100)
- Alcohol swabs
Step-by-Step Instructions
Choose your administration route
Injectable SubQ: most reliable absorption, 0.5–2mg dose. Nasal spray: convenient, slightly lower bioavailability. The FDA-approved form (Vyleesi) is a SubQ auto-injector at 1.75mg.
Reconstitute for injection
Add 2mL bacteriostatic water to a 10mg vial for 5mg/mL concentration. 1mg dose = 0.2mL = 20 units on a U-100 syringe.
Time your dose correctly
Inject 1–4 hours before anticipated sexual activity. PT-141 has a slow onset (45–90 minutes) and long duration (6–12 hours). Do not take more than once in 24 hours.
Manage common side effects
Nausea (most common): take with food, start at 0.5mg, use anti-nausea medication if needed. Flushing and facial redness: normal and transient. Transient increase in blood pressure: monitor if hypertensive.
Limit frequency of use
PT-141 is not intended for daily use. The FDA-approved protocol limits use to once per 24 hours and no more than once per month for chronic use. Research protocols vary.
Common Mistakes to Avoid
Starting at 2mg
Fix: Start at 0.5mg to assess nausea sensitivity. Many users find 1mg is fully effective with fewer side effects than 2mg.
Expecting immediate effects
Fix: PT-141 takes 45–90 minutes to reach peak effect. Plan timing accordingly.
Using PT-141 as a substitute for addressing underlying issues
Fix: PT-141 addresses symptoms, not causes. Psychological factors, relationship dynamics, and hormonal imbalances should also be addressed.
Frequently Asked Questions
Does PT-141 work for women?
Yes — PT-141 is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It increases sexual desire and arousal through central melanocortin receptor activation.
How does PT-141 differ from Viagra/Cialis?
Viagra and Cialis work peripherally (increasing blood flow to genitals). PT-141 works centrally (in the brain) to increase sexual desire and arousal. They can be complementary — PT-141 addresses desire; PDE5 inhibitors address physical response.
Is PT-141 safe?
PT-141 (bremelanotide/Vyleesi) is FDA-approved for women with HSDD. The main safety concern is transient blood pressure elevation. It is contraindicated in patients with cardiovascular disease or uncontrolled hypertension.
Peptides Covered in This Guide
Related Guides
Not sure which peptide is right for you?
Take our 5-minute quiz to get a personalized peptide recommendation based on your biology and goals.